ZYUS Life Sciences Corporation (TSXV:ZYUS)

Market Cap	52.05M -27.3%
Revenue (ttm)	465.00K +2.9%
Net Income	-33.74M
EPS	-0.45
Shares Out	80.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	506
Average Volume	9,172
Open	0.6500
Previous Close	0.6500
Day's Range	0.6500 - 0.6500
52-Week Range	0.4800 - 0.8700
Beta	0.78
RSI	47.95
Earnings Date	Apr 30, 2026

About ZYUS Life Sciences

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: ZYUS

Financial Performance

In 2024, ZYUS Life Sciences's revenue was 481,000, an increase of 37.04% compared to the previous year's 351,000. Losses were -33.81 million, -20.63% less than in 2023.